| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
As an impurity of lumateperone, this compound does not have a defined therapeutic target. Lumateperone itself targets multiple receptors including serotonin 5-HT2A receptors (antagonist), dopamine D2 receptors (antagonist), and serotonin transporter (SERT) (inhibitor). The impurity may have similar or different receptor binding properties, but its specific pharmacological profile has not been characterized.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for lumateperone-impurity are not available as it is not a therapeutic agent. The compound is used as a reference standard for analytical purposes rather than for pharmacological studies. Its biological activity, if any, has not been characterized.
|
| ln Vivo |
In vivo activity data for lumateperone-impurity are not available as it is not a therapeutic agent. The compound is not used in animal studies or clinical trials. Its primary use is as a reference standard for pharmaceutical quality control.
|
| Enzyme Assay |
Lumateperone-impurity is characterized and quantified using analytical methods such as high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), and mass spectrometry (MS). These methods are used to identify and quantify the impurity in lumateperone drug substance and drug products. The compound serves as a reference standard for method validation and quality control.
|
| Cell Assay |
As a reference standard, lumateperone-impurity is not used in cell-based assays. However, if its biological activity were to be assessed, standard cytotoxicity or receptor binding assays could be employed. The compound's primary use is in analytical method development and quality control, not in biological research.
|
| Animal Protocol |
As a reference standard, lumateperone-impurity is not used in animal studies. Its primary application is in pharmaceutical quality control laboratories for analytical method development and validation. The compound may be used in stability studies to monitor impurity levels in lumateperone drug products.
|
| ADME/Pharmacokinetics |
Lumateperone-impurity has CAS number 313368-85-3. It is a chemical compound identified as an impurity or related substance of lumateperone. The compound is typically stored as a reference standard at -20°C. Detailed physicochemical properties such as molecular weight and formula are not readily available in the public literature. The compound should be handled with appropriate laboratory safety precautions.
|
| Toxicity/Toxicokinetics |
Toxicological data for lumateperone-impurity are limited as it is a reference standard. As an impurity, its levels in pharmaceutical products are controlled to ensure patient safety. The compound's toxicity profile has not been extensively characterized. Standard laboratory safety precautions should be followed when handling the compound.
|
| Additional Infomation |
Lumateperone-impurity (CAS# 313368-85-3) is a chemical compound identified as an impurity or related substance of lumateperone (ITI-007), an antipsychotic drug approved for the treatment of schizophrenia. The impurity is used as a reference standard for analytical method development and quality control in pharmaceutical manufacturing. It is not a therapeutic agent and is not used in clinical or biological research.
|
| Molecular Formula |
C14H19N3
|
|---|---|
| Molecular Weight |
229.3208
|
| Exact Mass |
229.158
|
| CAS # |
313368-85-3
|
| PubChem CID |
21302499
|
| Appearance |
Solid Powder
|
| Density |
1.23±0.1g/cm3
|
| Boiling Point |
374.5±42.0°C
|
| LogP |
1.86
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
17
|
| Complexity |
306
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
N12C([H])([H])C([H])([H])N(C([H])([H])[H])C3=C([H])C([H])=C([H])C(=C13)[C@]1([H])C([H])([H])N([H])C([H])([H])C([H])([H])[C@@]21[H]
|
| InChi Key |
QLGUCSLWLPCOTR-RYUDHWBXSA-N
|
| InChi Code |
InChI=1S/C14H19N3/c1-16-7-8-17-12-5-6-15-9-11(12)10-3-2-4-13(16)14(10)17/h2-4,11-12,15H,5-9H2,1H3/t11-,12-/m0/s1
|
| Chemical Name |
(10R,15S)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-triene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3607 mL | 21.8036 mL | 43.6072 mL | |
| 5 mM | 0.8721 mL | 4.3607 mL | 8.7214 mL | |
| 10 mM | 0.4361 mL | 2.1804 mL | 4.3607 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
